Amicus Therapeutics Net Income vs. Price To Sales
| FOLD Stock | USD 14.35 0.01 0.07% |
Net Loss | First Reported 2004-12-31 | Previous Quarter 17.3 M | Current Value 1.7 M | Quarterly Volatility 32.5 M |
For Amicus Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Amicus Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Amicus Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Amicus Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Amicus Therapeutics over time as well as its relative position and ranking within its peers.
Check out Investing Opportunities. Will Biotechnology sector continue expanding? Could Amicus diversify its offerings? Factors like these will boost the valuation of Amicus Therapeutics. Market participants price Amicus higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Amicus Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.95) | Earnings Share (0.09) | Revenue Per Share | Quarterly Revenue Growth 0.237 | Return On Assets |
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Amicus Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Amicus Therapeutics Price To Sales vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Amicus Therapeutics's current stock value. Our valuation model uses many indicators to compare Amicus Therapeutics value to that of its competitors to determine the firm's financial worth. Amicus Therapeutics is rated below average in net income category among its peers. It is rated # 5 in price to sales category among its peers . At present, Amicus Therapeutics' Net Loss is projected to decrease significantly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Amicus Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Amicus Price To Sales vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Amicus Therapeutics |
| = | (27.11 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Amicus Therapeutics |
| = | 7.11 X |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Amicus Price To Sales Comparison
Amicus Therapeutics is currently under evaluation in price to sales category among its peers.
Amicus Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Amicus Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Amicus Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Amicus Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Amicus Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 24.1 M | 25.3 M | |
| Operating Income | 34.5 M | 36.2 M | |
| Income Before Tax | 191 K | 200.6 K | |
| Total Other Income Expense Net | -34.3 M | -32.6 M | |
| Net Loss | -27.1 M | -28.5 M | |
| Income Tax Expense | 27.3 M | 28.7 M | |
| Net Loss | -27.1 M | -28.5 M | |
| Non Operating Income Net Other | 6.5 M | 6.8 M | |
| Net Loss | -212.9 M | -223.6 M | |
| Interest Income | 3.3 M | 5 M | |
| Net Interest Income | -42.8 M | -40.7 M | |
| Change To Netincome | 89.2 M | 61.4 M | |
| Net Loss | (0.09) | (0.09) | |
| Income Quality | (1.22) | (1.16) | |
| Net Loss | (141.94) | (134.84) |
Amicus Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Amicus Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Amicus Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Amicus Therapeutics' important profitability drivers and their relationship over time.
Amicus Therapeutics Earnings Estimation Breakdown
The calculation of Amicus Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Amicus Therapeutics is estimated to be 0.1516 with the future projection ranging from a low of 0.1363 to a high of 0.18. Please be aware that this consensus of annual earnings estimates for Amicus Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.14 Lowest | Expected EPS | 0.18 Highest |
Amicus Therapeutics Earnings Projection Consensus
Suppose the current estimates of Amicus Therapeutics' value are higher than the current market price of the Amicus Therapeutics stock. In this case, investors may conclude that Amicus Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Amicus Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of June 2026 | Current EPS (TTM) | |
| 7 | 66.18% | 0.0 | 0.1516 | -0.09 |
Amicus Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Amicus Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Amicus Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Amicus Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Amicus Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Amicus Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Amicus Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Amicus Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Amicus Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2026-02-19 | 2025-12-31 | 0.065 | 0.1 | 0.035 | 53 | ||
2025-11-04 | 2025-09-30 | 0.03 | 0.06 | 0.03 | 100 | ||
2025-07-31 | 2025-06-30 | -0.11 | -0.08 | 0.03 | 27 | ||
2025-05-07 | 2025-03-31 | -0.07 | 0.03 | 0.1 | 142 | ||
2025-02-26 | 2024-12-31 | 0.0911 | 0.09 | -0.0011 | 1 | ||
2024-11-06 | 2024-09-30 | -0.01 | -0.02 | -0.01 | 100 | ||
2024-08-08 | 2024-06-30 | -0.06 | -0.05 | 0.01 | 16 | ||
2024-05-09 | 2024-03-31 | -0.07 | -0.16 | -0.09 | 128 | ||
2024-02-28 | 2023-12-31 | -0.06 | -0.11 | -0.05 | 83 | ||
2023-11-08 | 2023-09-30 | -0.08 | -0.07 | 0.01 | 12 | ||
2023-08-08 | 2023-06-30 | -0.12 | -0.15 | -0.03 | 25 | ||
2023-05-10 | 2023-03-31 | -0.15 | -0.18 | -0.03 | 20 | ||
2023-03-01 | 2022-12-31 | -0.13 | -0.19 | -0.06 | 46 | ||
2022-11-07 | 2022-09-30 | -0.19 | -0.12 | 0.07 | 36 | ||
2022-08-04 | 2022-06-30 | -0.22 | -0.21 | 0.01 | 4 | ||
2022-05-09 | 2022-03-31 | -0.25 | -0.3 | -0.05 | 20 | ||
2022-02-24 | 2021-12-31 | -0.16 | -0.29 | -0.13 | 81 | ||
2021-11-09 | 2021-09-30 | -0.17 | -0.19 | -0.02 | 11 | ||
2021-08-05 | 2021-06-30 | -0.21 | -0.19 | 0.02 | 9 | ||
2021-05-10 | 2021-03-31 | -0.23 | -0.25 | -0.02 | 8 | ||
2021-03-01 | 2020-12-31 | -0.22 | -0.27 | -0.05 | 22 | ||
2020-11-05 | 2020-09-30 | -0.22 | -0.23 | -0.01 | 4 | ||
2020-08-10 | 2020-06-30 | -0.26 | -0.2 | 0.06 | 23 | ||
2020-05-07 | 2020-03-31 | -0.28 | -0.34 | -0.06 | 21 | ||
2020-03-02 | 2019-12-31 | -0.27 | -0.35 | -0.08 | 29 | ||
2019-11-11 | 2019-09-30 | -0.32 | -0.24 | 0.08 | 25 | ||
2019-08-08 | 2019-06-30 | -0.33 | -0.36 | -0.03 | 9 | ||
2019-05-08 | 2019-03-31 | -0.31 | -0.39 | -0.08 | 25 | ||
2019-02-28 | 2018-12-31 | -0.28 | -0.41 | -0.13 | 46 | ||
2018-11-05 | 2018-09-30 | -0.28 | -0.31 | -0.03 | 10 | ||
2018-08-07 | 2018-06-30 | -0.33 | -0.33 | 0.0 | 0 | ||
2018-05-08 | 2018-03-31 | -0.36 | -0.28 | 0.08 | 22 | ||
2018-02-28 | 2017-12-31 | -0.3 | -0.41 | -0.11 | 36 | ||
2017-11-08 | 2017-09-30 | -0.31 | -0.41 | -0.1 | 32 | ||
2017-08-07 | 2017-06-30 | -0.36 | -0.34 | 0.02 | 5 | ||
2017-05-09 | 2017-03-31 | -0.36 | -0.39 | -0.03 | 8 | ||
2017-03-01 | 2016-12-31 | -0.33 | -0.42 | -0.09 | 27 | ||
2016-11-07 | 2016-09-30 | -0.31 | -0.33 | -0.02 | 6 | ||
2016-08-09 | 2016-06-30 | -0.33 | -0.4 | -0.07 | 21 | ||
2016-05-03 | 2016-03-31 | -0.34 | -0.35 | -0.01 | 2 | ||
2016-02-26 | 2015-12-31 | -0.3 | -0.36 | -0.06 | 20 | ||
2015-11-03 | 2015-09-30 | -0.25 | -0.32 | -0.07 | 28 | ||
2015-08-05 | 2015-06-30 | -0.24 | -0.26 | -0.02 | 8 | ||
2015-05-05 | 2015-03-31 | -0.2 | -0.25 | -0.05 | 25 | ||
2015-03-03 | 2014-12-31 | -0.18 | -0.24 | -0.06 | 33 | ||
2014-11-06 | 2014-09-30 | -0.21 | -0.22 | -0.01 | 4 | ||
2014-08-07 | 2014-06-30 | -0.23 | -0.22 | 0.01 | 4 | ||
2014-05-05 | 2014-03-31 | -0.24 | -0.25 | -0.01 | 4 | ||
2014-03-03 | 2013-12-31 | -0.32 | -0.18 | 0.14 | 43 | ||
2013-11-12 | 2013-09-30 | -0.34 | -0.29 | 0.05 | 14 | ||
2013-08-07 | 2013-06-30 | -0.35 | -0.31 | 0.04 | 11 | ||
2013-05-09 | 2013-03-31 | -0.33 | -0.35 | -0.02 | 6 | ||
2013-03-12 | 2012-12-31 | -0.37 | -0.2 | 0.17 | 45 | ||
2012-11-05 | 2012-09-30 | -0.24 | -0.34 | -0.1 | 41 | ||
2012-08-07 | 2012-06-30 | -0.23 | -0.2 | 0.03 | 13 | ||
2012-05-10 | 2012-03-31 | -0.35 | -0.35 | 0.0 | 0 | ||
2012-02-13 | 2011-12-31 | -0.37 | -0.25 | 0.12 | 32 | ||
2011-11-01 | 2011-09-30 | -0.33 | -0.28 | 0.05 | 15 | ||
2011-08-08 | 2011-06-30 | -0.32 | -0.37 | -0.05 | 15 | ||
2011-05-04 | 2011-03-31 | -0.35 | -0.39 | -0.04 | 11 | ||
2011-02-14 | 2010-12-31 | -0.15 | -0.48 | -0.33 | 220 | ||
2010-11-08 | 2010-09-30 | -0.49 | -0.56 | -0.07 | 14 | ||
2010-08-05 | 2010-06-30 | -0.53 | -0.41 | 0.12 | 22 | ||
2010-05-06 | 2010-03-31 | -0.58 | -0.54 | 0.04 | 6 | ||
2010-02-16 | 2009-12-31 | -0.59 | 1.45 | 2.04 | 345 | ||
2009-10-29 | 2009-09-30 | -0.68 | -0.59 | 0.09 | 13 | ||
2009-08-05 | 2009-06-30 | -0.65 | -0.6 | 0.05 | 7 | ||
2009-05-07 | 2009-03-31 | -0.64 | -0.55 | 0.09 | 14 | ||
2009-02-05 | 2008-12-31 | -0.62 | -0.63 | -0.01 | 1 | ||
2008-11-03 | 2008-09-30 | -0.47 | -0.36 | 0.11 | 23 | ||
2008-08-07 | 2008-06-30 | -0.51 | -0.41 | 0.1 | 19 | ||
2008-05-13 | 2008-03-31 | -0.38 | -0.34 | 0.04 | 10 | ||
2008-01-29 | 2007-12-31 | -0.4 | -0.53 | -0.13 | 32 | ||
2007-10-31 | 2007-09-30 | -0.46 | -0.46 | 0.0 | 0 | ||
2007-08-07 | 2007-06-30 | -0.48 | -1.37 | -0.89 | 185 |
Use Amicus Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amicus Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amicus Therapeutics will appreciate offsetting losses from the drop in the long position's value.Amicus Therapeutics Pair Trading
Amicus Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Amicus Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amicus Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amicus Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amicus Therapeutics to buy it.
The correlation of Amicus Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amicus Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amicus Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Amicus Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Amicus Therapeutics position
In addition to having Amicus Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Broad Equity ETFs Thematic Idea Now
Broad Equity ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Equity ETFs theme has 548 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Equity ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Investing Opportunities. For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
To fully project Amicus Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Amicus Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Amicus Therapeutics' income statement, its balance sheet, and the statement of cash flows.